GLPG Share Price Performance
€27.50
2.68 (10.80%)
Price €27.50
Share Price€27.50
Galapagos NV Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
GLPG Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Galapagos NV Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 05, 2025
- -4.38
- 39.41%
- -104.66%
- 0%
About GLPG
- Founded
- 1999
- Employees
- 558
- CEO
- WebsiteView website
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
